Navigation Links
Egon Zehnder International Names Todd Hutchings to Lead Life Sciences Practice Group
Date:12/6/2010

LOS ANGELES, Dec. 6, 2010 /PRNewswire/ -- Todd Hutchings has assumed leadership of Egon Zehnder International's North American Life Sciences Practice Group.  Peter Levin, who led the practice, will continue at the firm in an active client-facing role recruiting CEOs and C-Level executives.

In his new role, Mr. Hutchings will be responsible for deepening core client relationships, working with boards and providing the full array of functional leadership capabilities to Life Science companies. Since joining EZI in 2005, Mr. Hutchings has been a critical member of the practice, working across a wide variety of functions and life sciences segments and developing a specialty in diagnostics and biotech. 

Prior to joining EZI, he served as Director, Business Planning for Roche Diagnostics and as a consultant for McKinsey & Company and The Monitor Group.

"Todd Hutchings has played a vital role in the growth of the LSPG. We are looking forward to his experience and insights in his new leadership position," said Karena Strella, Managing Partner of the firm's California Practice.

Mr. Hutchings earned his Honors Bachelor of Commerce degree from McMaster University and his MBA from the Richard Ivey School of Business. He resides in Los Angeles.

About Egon Zehnder International

Egon Zehnder International is one of the largest privately-held executive search firms in the world with nearly 400 consultants operating from 63 wholly owned offices in 37 countries.  The firm specializes in senior-level executive search, board consulting and director search, management appraisals, and talent management.  Egon Zehnder International's clients range in size from the world's largest corporations to emerging growth companies to government and regulatory bodies and major educational and cultural organizations. Egon Zehnder International has sector specialists organized into global practices. These include Industrial, Financial Services, Consumer, Life Sciences, Technology & Communications, Services, Private Capital and Sovereign Wealth Funds. For more information visit  www.egonzehnder.com.


'/>"/>
SOURCE Egon Zehnder International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
2. Yongye Biotechnology International Retains CCG Investor Relations
3. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
4. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
5. Yongye Biotechnology International Announces Second Quarter Results
6. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
7. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
8. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
9. Mindray Medical International Announces Second Quarter 2008 Results
10. Singapore to hold international pow-wow
11. Sangui BioTech International, Inc. Files Remaining Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
(Date:12/8/2016)... Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: ... develops and plans to commercialize innovative therapeutics for ... common stock were approved for trading on the ... on the OTCQX, effective today, under the ticker ... OTCQX market, companies must meet high financial standards, ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 8, 2016   Biocept, Inc . (NASDAQ: ... of clinically actionable liquid biopsy tests to improve ... data featuring its Target Selectorâ„¢ Circulating Tumor Cell ... the detection of actionable biomarkers in patients with ... by Sara Cannon Research Institute (SCRI), the research ...
Breaking Biology Technology:
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
(Date:12/5/2016)... -- The Office of Justice Programs, National Institute of ... or Replace Medico Legal Autopsies?" on NIJ.gov.  The ... forensic autopsies with postmortem X-ray computed tomography, commonly ... to recommendations made by The National Academy of ... a potential component of medicolegal death investigations. NIJ,s ...
Breaking Biology News(10 mins):